Literature DB >> 25747663

Towards an HIV-1 cure: measuring the latent reservoir.

Katherine M Bruner1, Nina N Hosmane1, Robert F Siliciano2.   

Abstract

The latent reservoir (LR) of HIV-1 in resting memory CD4(+) T cells serves as a major barrier to curing HIV-1 infection. While many PCR- and culture-based assays have been used to measure the size of the LR, correlation between results of different assays is poor and recent studies indicate that no available assay provides an accurate measurement of reservoir size. The discrepancies between assays are a hurdle to clinical trials that aim to measure the efficacy of HIV-1 eradication strategies. Here we describe the advantages and disadvantages of various approaches to measuring the LR.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HIV-1; assays; cure; latency

Mesh:

Year:  2015        PMID: 25747663      PMCID: PMC4386620          DOI: 10.1016/j.tim.2015.01.013

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  108 in total

Review 1.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

2.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Authors:  Josep M Llibre; Maria J Buzón; Marta Massanella; Anna Esteve; Viktor Dahl; Maria C Puertas; Pere Domingo; Josep M Gatell; Maria Larrouse; Mar Gutierrez; Sarah Palmer; Mario Stevenson; Julià Blanco; Javier Martinez-Picado; Bonaventura Clotet
Journal:  Antivir Ther       Date:  2011-09-28

4.  Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.

Authors:  Angela M Mexas; Erin H Graf; Matthew J Pace; Jianqing J Yu; Emmanouil Papasavvas; Livio Azzoni; Michael P Busch; Michele Di Mascio; Andrea S Foulkes; Stephen A Migueles; Luis J Montaner; Una O'Doherty
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

5.  Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.

Authors:  M Arnedo-Valero; F Garcia; C Gil; T Guila; E Fumero; P Castro; J L Blanco; J M Miró; T Pumarola; J M Gatell
Journal:  Clin Infect Dis       Date:  2005-08-04       Impact factor: 9.079

6.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

7.  Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi.

Authors:  Julia Luebbert; Hannock Tweya; Sam Phiri; Thom Chaweza; Johnbosco Mwafilaso; Mina C Hosseinipour; Heribert Ramroth; Paul Schnitzler; Florian Neuhann
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

8.  Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Authors:  Steven A Yukl; Eli Boritz; Michael Busch; Christopher Bentsen; Tae-Wook Chun; Daniel Douek; Evelyn Eisele; Ashley Haase; Ya-Chi Ho; Gero Hütter; J Shawn Justement; Sheila Keating; Tzong-Hae Lee; Peilin Li; Danielle Murray; Sarah Palmer; Christopher Pilcher; Satish Pillai; Richard W Price; Meghan Rothenberger; Timothy Schacker; Janet Siliciano; Robert Siliciano; Elizabeth Sinclair; Matt Strain; Joseph Wong; Douglas Richman; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

9.  Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.

Authors:  Gregory M Laird; Evelyn E Eisele; S Alireza Rabi; Jun Lai; Stanley Chioma; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

10.  Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Authors:  Datsen George Wei; Vicki Chiang; Elizabeth Fyne; Mini Balakrishnan; Tiffany Barnes; Michael Graupe; Joseph Hesselgesser; Alivelu Irrinki; Jeffrey P Murry; George Stepan; Kirsten M Stray; Angela Tsai; Helen Yu; Jonathan Spindler; Mary Kearney; Celsa A Spina; Deborah McMahon; Jacob Lalezari; Derek Sloan; John Mellors; Romas Geleziunas; Tomas Cihlar
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

View more
  118 in total

1.  RNAP II processivity is a limiting step for HIV-1 transcription independent of orientation to and activity of endogenous neighboring promoters.

Authors:  Katarzyna Kaczmarek Michaels; Frank Wolschendorf; Gillian M Schiralli Lester; Malini Natarajan; Olaf Kutsch; Andrew J Henderson
Journal:  Virology       Date:  2015-09-14       Impact factor: 3.616

2.  HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo.

Authors:  John K Bui; John W Mellors; Anthony R Cillo
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

3.  Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA.

Authors:  Alexander O Pasternak; Laura K DeMaster; Neeltje A Kootstra; Peter Reiss; Una O'Doherty; Ben Berkhout
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

4.  Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Authors:  Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

5.  Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children.

Authors:  Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

6.  Genetically Intact but Functionally Impaired HIV-1 Env Glycoproteins in the T-Cell Reservoir.

Authors:  Anne de Verneuil; Julie Migraine; Fabrizio Mammano; Jean-Michel Molina; Sébastien Gallien; Hugo Mouquet; Allan J Hance; François Clavel; Jacques Dutrieux
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

7.  Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.

Authors:  Blake J Rust; Leslie S Kean; Lucrezia Colonna; Katherine E Brandenstein; Nikhita H Poole; Willimark Obenza; Mark R Enstrom; Colby R Maldini; Gavin I Ellis; Christine M Fennessey; Meei-Li Huang; Brandon F Keele; Keith R Jerome; James L Riley; Hans-Peter Kiem; Christopher W Peterson
Journal:  Blood       Date:  2020-10-08       Impact factor: 22.113

8.  Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics.

Authors:  Weiming Yang; Brooks Jackson; Hui Zhang
Journal:  Proteomics       Date:  2016-06-08       Impact factor: 3.984

9.  Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.

Authors:  Wen Shi Lee; Jonathan Richard; Marit Lichtfuss; Amos B Smith; Jongwoo Park; Joel R Courter; Bruno N Melillo; Joseph G Sodroski; Daniel E Kaufmann; Andrés Finzi; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

Review 10.  Tools for Visualizing HIV in Cure Research.

Authors:  Julia Niessl; Amy E Baxter; Daniel E Kaufmann
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.